Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Jounce Therapeutics

Request full access

A clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to…

Cambridge, United StatesFounded 2013Biotech & Life Sciences

About Jounce Therapeutics

Jounce Therapeutics, Inc. was a clinical-stage biopharmaceutical company that operated in the immuno-oncology market. Founded in 2013 by a team of world leaders in tumor immunology and cancer biology, including James P. Allison, who was later a co-recipient of the 2018 Nobel Prize in Physiology or Medicine for his work on cancer therapy. The company was launched with initial funding from life sciences investor Third Rock Ventures and was headquartered in Cambridge, Massachusetts.

The company's business model centered on the discovery and development of novel cancer immunotherapies and predictive biomarkers. Jounce utilized a proprietary Translational Science Platform to analyze the tumor microenvironment, which helped in prioritizing targets and identifying biomarkers to match therapies to the most suitable patients. Revenue generation was linked to the advancement of its product candidates through clinical trials and strategic collaborations, such as a major partnership with Celgene in 2016 and an exclusive license agreement with Gilead Sciences in 2020 for its JTX-1811 program.

Jounce's pipeline included several monoclonal antibodies. Its most advanced product candidate was vopratelimab (formerly JTX-2011), an antibody designed to activate the ICOS protein on T-cells to stimulate an immune response against tumors. Another key program was JTX-8064, a LILRB2 receptor antagonist aimed at reprogramming immune-suppressive macrophages within tumors. The company also developed its own PD-1 inhibitor, pimivalimab (JTX-4014), intended for use in combination with its other pipeline assets. However, the company faced significant clinical setbacks, including disappointing results from Phase 2 trials for vopratelimab in 2020 and 2022, which led to a reevaluation of the program.

Following these clinical trial failures and financial pressures, Jounce announced a 57% workforce reduction in February 2023. The company initially entered into a reverse merger agreement with Redx Pharma. This plan was soon superseded by an acquisition offer from Concentra Biosciences, LLC. In March 2023, Jounce agreed to be acquired by Concentra for approximately $97.5 million in cash plus contingent value rights. The acquisition was completed in May 2023, leading to further layoffs and the cessation of Jounce's clinical development programs.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2017

Jounce Therapeutics in the Cambridge ecosystem

Live from Dealroom

The Jounce Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

22 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A10 investors entered at this stage

Series B and later12 investors entered at this stage

Team profiled 28 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$15M

12 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Jounce Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.